Ask AI
2L Therapy for PV and ET

CME

Preparing for the Future: Integration of Second-line Therapies After Hydroxyurea for PV and ET

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 29, 2026

Expiration: October 28, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Pankit Vachhani, MD, discusses the evidence informing second-line treatment options for patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant to initial cytoreductive therapy. The discussion includes currently approved therapies and emerging strategies for novel treatment approaches.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with ET or PV do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following agents is an LSD1 inhibitor that has shown promising durable platelet reductions for patients with ET and good hematocrit control in patients with PV who are resistant or intolerant to current cytoreductive therapy?